ATP6V0A1 Antibody

Immunocytochemistry/ Immunofluorescence: ATP6V0A1 Antibody [NBP1-89342]

Immunocytochemistry/Immunofluorescence: ATP6V0A1 Antibody [NBP1-89342] - Staining of human cell line A-431 shows localization to the Golgi apparatus & vesicles. Antibody staining is shown in green.

Immunohistochemistry-Paraffin: ATP6V0A1 Antibody [NBP1-89342]

Immunohistochemistry-Paraffin: ATP6V0A1 Antibody [NBP1-89342] - Staining of human cerebral cortex shows strong cytoplasmic positivity in neuropil.

Immunohistochemistry-Paraffin: ATP6V0A1 Antibody [NBP1-89342]

Immunohistochemistry-Paraffin: ATP6V0A1 Antibody [NBP1-89342] - Staining of human tonsil shows low expression as expected.

Immunohistochemistry-Paraffin: ATP6V0A1 Antibody [NBP1-89342]

Immunohistochemistry-Paraffin: ATP6V0A1 Antibody [NBP1-89342] - Staining of human kidney shows strong cytoplasmic postivity in cells in tubules.

Immunohistochemistry-Paraffin: ATP6V0A1 Antibody [NBP1-89342]

Immunohistochemistry-Paraffin: ATP6V0A1 Antibody [NBP1-89342] - Staining of human cerebellum shows strong cytoplasmic postivity in cells in granular layer.

Immunocytochemistry/ Immunofluorescence: ATP6V0A1 Antibody [NBP1-89342] -

Immunocytochemistry/ Immunofluorescence: ATP6V0A1 Antibody [NBP1-89342] - In Cln1−/− mice V0a1 is misrouted to plasma membrane preventing its interaction with AP-3.(a) Western blot analysis & densitometric quantitation of V0a1 in isolated plasma membrane fraction from WT & Cln1−/− mouse brain (n=4, *P<0.05). (b) Localization of V0a1 in the plasma membrane in WT & Cln1−/− neurons using Na+, K+-ATPase as membrane marker. Colocalization between V0a1 & Na+, K+-ATPase was assessed using the Manders' colocalization coefficients M1 & M2 (n=18 for WT & n=22 for Cln1−/−, ***P<0.001; scale bars, 5 μm. (c) Pull-down assay with AP-3 antibody detects V0a1 in total brain lysates from WT & Cln1−/− mouse brain (n=4, *P<0.05). (d) Confocal imaging of PLA reaction showing V0a1 & AP-3 delta interaction in neurons isolated from WT & Cln1−/−mouse brain (n=188 for WT & n=158 for Cln1−/−, ***P<0.001); scale bars, 20 μm. (e) Pull-down assay with AP-3 antibody using total lysates from untreated (lane 1) & bromopalmitate-treated (lane 2) WT brain slices to detect V0a1 & its densitometric quantitation (n=4, *P<0.05). (f) HEK-293 cells were transfected with WT GFP-V0a1 & GFP-V0a1-Cys25Ser mutant construct, & pull-down experiments were conducted with AP-3 antibody to detect GFP-V0a1,*P<0.05(n=4). Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/ncomms14612), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ATP6V0A1 Antibody [NBP1-89342] -

Western Blot: ATP6V0A1 Antibody [NBP1-89342] - In Cln1−/− mice V0a1 is misrouted to plasma membrane preventing its interaction with AP-3.(a) Western blot analysis & densitometric quantitation of V0a1 in isolated plasma membrane fraction from WT & Cln1−/− mouse brain (n=4, *P<0.05). (b) Localization of V0a1 in the plasma membrane in WT & Cln1−/− neurons using Na+, K+-ATPase as membrane marker. Colocalization between V0a1 & Na+, K+-ATPase was assessed using the Manders' colocalization coefficients M1 & M2 (n=18 for WT & n=22 for Cln1−/−, ***P<0.001; scale bars, 5 μm. (c) Pull-down assay with AP-3 antibody detects V0a1 in total brain lysates from WT & Cln1−/− mouse brain (n=4, *P<0.05). (d) Confocal imaging of PLA reaction showing V0a1 & AP-3 delta interaction in neurons isolated from WT & Cln1−/−mouse brain (n=188 for WT & n=158 for Cln1−/−, ***P<0.001); scale bars, 20 μm. (e) Pull-down assay with AP-3 antibody using total lysates from untreated (lane 1) & bromopalmitate-treated (lane 2) WT brain slices to detect V0a1 & its densitometric quantitation (n=4, *P<0.05). (f) HEK-293 cells were transfected with WT GFP-V0a1 & GFP-V0a1-Cys25Ser mutant construct, & pull-down experiments were conducted with AP-3 antibody to detect GFP-V0a1,*P<0.05(n=4). Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/ncomms14612), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: ATP6V0A1 Antibody [NBP1-89342] -

Immunocytochemistry/ Immunofluorescence: ATP6V0A1 Antibody [NBP1-89342] - In Cln1−/− mice V0a1 is misrouted to plasma membrane preventing its interaction with AP-3.(a) Western blot analysis & densitometric quantitation of V0a1 in isolated plasma membrane fraction from WT & Cln1−/− mouse brain (n=4, *P<0.05). (b) Localization of V0a1 in the plasma membrane in WT & Cln1−/− neurons using Na+, K+-ATPase as membrane marker. Colocalization between V0a1 & Na+, K+-ATPase was assessed using the Manders' colocalization coefficients M1 & M2 (n=18 for WT & n=22 for Cln1−/−, ***P<0.001; scale bars, 5 μm. (c) Pull-down assay with AP-3 antibody detects V0a1 in total brain lysates from WT & Cln1−/− mouse brain (n=4, *P<0.05). (d) Confocal imaging of PLA reaction showing V0a1 & AP-3 delta interaction in neurons isolated from WT & Cln1−/−mouse brain (n=188 for WT & n=158 for Cln1−/−, ***P<0.001); scale bars, 20 μm. (e) Pull-down assay with AP-3 antibody using total lysates from untreated (lane 1) & bromopalmitate-treated (lane 2) WT brain slices to detect V0a1 & its densitometric quantitation (n=4, *P<0.05). (f) HEK-293 cells were transfected with WT GFP-V0a1 & GFP-V0a1-Cys25Ser mutant construct, & pull-down experiments were conducted with AP-3 antibody to detect GFP-V0a1,*P<0.05(n=4). Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/ncomms14612), licensed under a CC-BY license. Not internally tested by Novus Biologicals.